Life Science Tools Maker Revvity Delivers Strong Q1 Earnings Despite Evolving Macroeconomic Backdrop

1. Revvity reports Q1 2025 earnings beat expectations, driving stock up 5%. 2. Q1 sales of $664.76 million surpassed consensus expectations despite a revenue decline. 3. Adjusted EPS of $1.01 exceeded consensus of 95 cents, reflecting strong performance. 4. Company raises 2025 sales guidance to $2.85 billion, affirming positive outlook. 5. CEO states Q1 performance positions Revvity well for future in evolving macroeconomics.